Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SUPT6H_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SUPT6H_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SUPT6H_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SUPT6H_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00082132 | Liver | HCC | protein alkylation | 111/7958 | 181/18723 | 2.36e-07 | 4.18e-06 | 111 |
GO:000170111 | Liver | HCC | in utero embryonic development | 204/7958 | 367/18723 | 2.44e-07 | 4.30e-06 | 204 |
GO:000636811 | Liver | HCC | transcription elongation from RNA polymerase II promoter | 50/7958 | 69/18723 | 4.32e-07 | 7.22e-06 | 50 |
GO:00064061 | Liver | HCC | mRNA export from nucleus | 44/7958 | 59/18723 | 5.61e-07 | 8.98e-06 | 44 |
GO:00714271 | Liver | HCC | mRNA-containing ribonucleoprotein complex export from nucleus | 44/7958 | 59/18723 | 5.61e-07 | 8.98e-06 | 44 |
GO:005105221 | Liver | HCC | regulation of DNA metabolic process | 198/7958 | 359/18723 | 7.62e-07 | 1.17e-05 | 198 |
GO:00315031 | Liver | HCC | protein-containing complex localization | 129/7958 | 220/18723 | 9.38e-07 | 1.42e-05 | 129 |
GO:00165712 | Liver | HCC | histone methylation | 88/7958 | 141/18723 | 1.41e-06 | 2.02e-05 | 88 |
GO:0032784 | Liver | HCC | regulation of DNA-templated transcription, elongation | 39/7958 | 53/18723 | 4.34e-06 | 5.53e-05 | 39 |
GO:00310601 | Liver | HCC | regulation of histone methylation | 46/7958 | 69/18723 | 4.30e-05 | 4.20e-04 | 46 |
GO:0034243 | Liver | HCC | regulation of transcription elongation from RNA polymerase II promoter | 25/7958 | 32/18723 | 4.38e-05 | 4.26e-04 | 25 |
GO:00349681 | Liver | HCC | histone lysine methylation | 70/7958 | 115/18723 | 5.32e-05 | 5.04e-04 | 70 |
GO:00327863 | Liver | HCC | positive regulation of DNA-templated transcription, elongation | 21/7958 | 27/18723 | 2.06e-04 | 1.59e-03 | 21 |
GO:00018251 | Liver | HCC | blastocyst formation | 27/7958 | 38/18723 | 3.47e-04 | 2.42e-03 | 27 |
GO:00468312 | Liver | HCC | regulation of RNA export from nucleus | 11/7958 | 12/18723 | 5.97e-04 | 3.75e-03 | 11 |
GO:000632511 | Liver | HCC | chromatin organization | 206/7958 | 409/18723 | 7.23e-04 | 4.41e-03 | 206 |
GO:00180221 | Liver | HCC | peptidyl-lysine methylation | 74/7958 | 131/18723 | 8.46e-04 | 5.06e-03 | 74 |
GO:00329681 | Liver | HCC | positive regulation of transcription elongation from RNA polymerase II promoter | 11/7958 | 13/18723 | 2.38e-03 | 1.16e-02 | 11 |
GO:0031057 | Liver | HCC | negative regulation of histone modification | 29/7958 | 46/18723 | 3.95e-03 | 1.74e-02 | 29 |
GO:0002200 | Liver | HCC | somatic diversification of immune receptors | 44/7958 | 77/18723 | 6.70e-03 | 2.72e-02 | 44 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SUPT6H | SNV | Missense_Mutation | | c.388N>T | p.Asp130Tyr | p.D130Y | Q7KZ85 | protein_coding | deleterious(0) | possibly_damaging(0.791) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
SUPT6H | SNV | Missense_Mutation | | c.5009N>G | p.Ala1670Gly | p.A1670G | Q7KZ85 | protein_coding | tolerated(0.37) | benign(0.066) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
SUPT6H | SNV | Missense_Mutation | rs755836482 | c.4562N>C | p.Gly1521Ala | p.G1521A | Q7KZ85 | protein_coding | tolerated(0.12) | possibly_damaging(0.505) | TCGA-A8-A08B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
SUPT6H | SNV | Missense_Mutation | | c.3218N>T | p.Ala1073Val | p.A1073V | Q7KZ85 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SUPT6H | SNV | Missense_Mutation | | c.3817N>C | p.Glu1273Gln | p.E1273Q | Q7KZ85 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SUPT6H | SNV | Missense_Mutation | | c.295G>A | p.Asp99Asn | p.D99N | Q7KZ85 | protein_coding | deleterious(0.01) | probably_damaging(0.956) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
SUPT6H | SNV | Missense_Mutation | | c.298N>A | p.Asp100Asn | p.D100N | Q7KZ85 | protein_coding | deleterious(0.02) | probably_damaging(0.956) | TCGA-C8-A131-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
SUPT6H | SNV | Missense_Mutation | | c.3779G>C | p.Gly1260Ala | p.G1260A | Q7KZ85 | protein_coding | deleterious(0.02) | possibly_damaging(0.705) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
SUPT6H | SNV | Missense_Mutation | | c.22N>A | p.Glu8Lys | p.E8K | Q7KZ85 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.905) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SUPT6H | SNV | Missense_Mutation | | c.388G>T | p.Asp130Tyr | p.D130Y | Q7KZ85 | protein_coding | deleterious(0) | possibly_damaging(0.791) | TCGA-D8-A1X7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | ChemotherapyHormone Therapy | doxorubicine+cyclophosphamide+tamoxifen | SD |